Harrow To Acquire Certain US And Canadian Commercial Rights For Specific Branded Products From Santen Pharmaceutical; Terms Not Disclosed
Portfolio Pulse from Benzinga Newsdesk
Harrow is set to acquire certain US and Canadian commercial rights for specific branded products from Santen Pharmaceutical. The terms of the deal were not disclosed. Harrow expects the transaction to reduce its aggregate leverage ratio of adjusted EBITDA to debt. The transaction was financed through the expansion of Harrow's secured credit facility with funds managed by Oaktree Capital Management.
July 18, 2023 | 9:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Harrow's acquisition of commercial rights from Santen Pharmaceutical is expected to reduce its leverage ratio. The transaction was financed through an expanded credit facility with Oaktree Capital Management.
The acquisition is expected to reduce Harrow's leverage ratio, which is generally seen as a positive move by investors as it reduces financial risk. This could lead to a positive impact on Harrow's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100